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Purpose: It is difficult to obtain biopsies from gastrointestinal stromal tumors (GISTs) prior to surgery because GISTs are submucoal tu-
mors, despite being the most common nonepithelial neoplasms of the gastrointestinal tract. Unlike anatomic imaging techniques, PET-
CT, which is a molecular imaging tool, can be a useful technique for assessing tumor activity and predicting the malignant potential of 
certain tumors. Thus, we aimed to evaluate the usefulness of PET-CT as a pre-operative prognostic factor for GISTs by analyzing the cor-
relation between the existing post-operative prognostic factors and the maximum SUV uptake (SUVmax) of pre-operative 18F-fluoro-2-
deoxyglucose (FDG) PET-CT.
Materials and Methods: The study was conducted on 26 patients who were diagnosed with gastric GISTs and underwent surgery after 
being examined with pre-operative FDG PET-CT. An analysis of the correlation bewteen (i) NIH risk classfication and the Ki-67 prolifera-
tion index, which are post-operative prognostic factors, and (ii) the SUVmax of PET-CT, which is a pre-operative prognostic factor, was 
performed.
Results: There were significant correlations between (i) SUVmax and (ii) Ki-67 index, tumor size, mitotic count, and NIH risk group 
(r=0.854, 0.888, 0.791, and 0.756, respectively). The optimal cut-off value for SUVmax was 3.94 between “low-risk malignancy” 
and “high-risk malignancy” groups. The sensitivity and specificity of SUVmax for predicting the risk of malignancy were 85.7% and 
94.7%, respectively.
Conclusions: The SUVmax of PET-CT is associated with Ki-67 index, tumor size, mitotic count, and NIH classification. Therefore, it is 
believed that PET-CT is a relatively safe, non-invasive diagnostic tool for assessing malignant potential pre-operatively.
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Introduction
Gastrointestinal stromal tumors (GISTs), which are the most 
common mesenchymal tumors arising within the gastrointes-
tinal tract and a neoplasm differentiated through the malignant 
transformation of interstitial cells of Cajal (ICC). GISTs develop 
in decreasing order of frequency in the stomach, small intestine, 
large intestine, and esophagus; GISTs represent 0.1~0.3% of all 
gastrointestinal tumors.(1,2) The stomach is the most common site 
at which GISTs develop.(3)
GISTs are CD117 (c-kit)- or CD34-positive,(4) with positive 
rates of 94% and 60~70%, respectively.(5) Therefore, immunohis-
tochemical staining allows a differential diagnosis between GISTs 
and existing submucosal tumors.
To predict the prognosis for these GISTs, pathologic factors, 
including the tumor size, mitotic count, c-kit mutation, tumor ne-
crosis, cellular necrosis, interstitial necrosis, and lesion site are usu-
ally used, but such pathologic factors are not sufficient to make an Park JW, et al.
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objective prediction because GISTs exhibit various clinical features. 
A number of recent studies have evaluated the biological indices 
which are of use as prognostic factors in malignant tumors, such as 
gastric, lung, and breast cancers, for similar utility in the prognosis 
for GISTs, reporting the genetic mutation of c-kit and cell prolif-
eration, including the Ki-67 proliferation index, proliferation cell 
nuclear antigen (PCNA), flow cytometry, and p53.(6-8)
In predicting prognosis based on post-operative factors, Amin 
et al.(9) classified tumors into benign, borderline, and malignant 
based on tumor size and mitotic count, while the National Institutes 
of Health (NIH) consensus conference in 2001 divided the tumors 
into very low-, low-, intermediate-, and high-risk based on the 
risk of malignancy,(10) which is widely used for predicting post-
operative malignant potential (Table 1). However, there is no meth-
od with which to predict the pre-operative prognosis for GISTs, 
with the exception of measuring tumor size using anatomic imag-
ing techniques, such as computed tomography (CT), endoscopic 
ultrasonography (EUS), and magnetic resonance imaging (MRI).
Recently, the use of PET-CT as a non-invasive diagnostic 
tool in oncology for diagnosis and staging, as well as a technique 
to determine prognosis and the best course of treatment, has in-
creased. PET-CT is expected to be useful as a non-invasive tool, 
especially for GISTs, because the pre-operative diagnosis, staging, 
and prediction of prognosis of GISTs is not easy.(11,12) Indeed, all 
GISTs have the potential for malignant transformation and there is 
no pre-operative diagnostic method that distinguishes GISTs from 
submucosal tumors.
The objective of the current study was to determine if PET-
CT is clinically useful for predicting the pre-operative prognosis 
of GISTs by comparing the pre-operative maximum standard-
ized uptake value (SUV) uptake (SUVmax) of the 18F-fluoro-2-
deoxyglucose (FDG) PET-CT, which is a molecular imaging tool, 
with existing post-operative prognostic factors, such as the tumor 




The study was conducted on 26 of 27 patients who were diag-
nosed with gastric submucosal tumors and underwent surgery after 
a pre-operative FDG PET-CT at the Catholic University of Dae-
gue between Feburary 2007 and Feburary of 2009 (11 males and 16 
females); 1 patient with a leiomyoma was excluded. The 2001 NIH 
risk classification (tumor size and mitotic count) and Ki-67 prolif-
eration index were investigated regarding post-operative prognosis 
factors, and the correlation with the SUVmax of the FDG PET-CT 
as a pre-operative prognostic factor was retrospectively compared 
and analyzed. None of the patients had distant metastases. None of 
the patients had diabetes, and the blood glucose level in all patents 
were ＜100 mg/dl at the time of the PET scan. To evaluate malig-
nant potential, we classified the NIH risk classification as “low-risk 
malignancy” (very low-risk and low-risk) and “high-risk malig-
nancy” groups (intermediate-risk and high-risk). The study design 
was approved by the IRB of the Catholic University Medical Center 
of Daegu, and informed consent was obtained from all patients.
2. Diagnosis of gastric GIST
After the FDG PET-CT study, each patient underwent tumor 
resection. Eleven patients had laparoscopic wedge resections of the 
stomach, 13 patients had open wedge resections, and 2 patients had 
gastrectomies. Post-operatively, GIST was diagnosed by positive 
staining of c-kit, CD34, or both.
3. Ki-67 Immunohistochemisty
The surgical specimens were fixed with 10% neutral buffered 
formalin and embedded in paraffin blocks. Hematoxylin and eosin 
staining were performed. Immunohistochemical staining for c-kit 
and CD34 was performed by the standard avidin-biotin peroxidase 
complex method, and the Ki-67 proliferation index was deter-
mined. The Ki-67 index was defined as the percentage of nuclear-
stained tumor cells per 1,000 tumor cells and evaluated by 1 pa-
thologist to reduce bias. 





Very low risk <2 cm <5
Low risk 2~5 cm <5
Intermediate risk <5 cm 6 ~10
5~10 cm <5
High risk >5 cm >5
>10 cm Any mitotic rate
Any size >10
HPF = high-power fi  elds. *Size is the single largest dimension. Role of PET-CT in GIST
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4. PET-CT imaging
All patients fasted for at least 6 hours before the injection of 
tracer, then injected with 200 MBq of FDG. PET images were ac-
quired 50 minutes after the administration of FDG. With the patient 
in the supine position on the scanner (GE Advance; GE Medical 
Systems, Milwaukee, WI, USA), a whole-body emission scan was 
obtained followed by a transmission scan for attenuation correction. 
A semi-quantitative analysis was simultaneously performed by cal-
culating the SUV of FDG in the affected areas, as follows:
SUV=
Tissue activity (μCi/ml)
Injected activity mCi/weight (kg)
5. Statistical analysis
To test the association between pre-operative (the SUVmax of 
the PET-CT) and post-operative prognostic factors, we calculated 
Pearson’s and Spearman’s correlation coefficients. To determine the 
cut-off level of the MSU of the PET-CT, we retrospectively pre-
pared a receiver-operating characteristic (ROC) curve based on the 
results. A P＜0.05 was considered significant.
Results
1. Clinical characteristics of the patients 
The clinico-pathologic characteristics of the 26 patients studied 
are summarized in Table 2. We studied 26 patients (10 males and 
16 females) with a GIST of the stomach. The mean age was 62.04
±11.4 years. All tumors stained positive for c-kit, CD 34, or both. 
FDG uptake was found demonstrated in all cases. 
GISTs were primarily located in the proximal body (12 patients 
[46.2%]); the tumor size was 2~5 cm (15 patients [57.7%]). The 
majority of mitotic counts were 5/50 high-power fields (HPF), 
with none exceeding 10/50 HPF. The NIH risk classification 
was divided into very low- (2 patients [7.7%]), low- (17 patients 
[65.4%]), intermediate- (5 patients [19.2%]), and high-risk groups (2 
patients [7.7%]).
2. Relationship between maximum SUV uptake and 
clinicopathologic characteristics 
The relationships between the maximum SUV uptake and the 
clinicopathologic characteristics of gastric GISTs, including tumor 
size, Ki-67 index, mitotic count, and NIH risk group, are shown 
in Table 3. As a result of an analysis of the correlation between 
the maximum SUV and other prognostic factors, the correlation 
coefficient of the MSU with Ki-67, mitotic count, tumor size, and 
NIH risk classification was 0.854 (P=0.000), 0.888 (P=0.000), 0.791 
(P=0.000), and 0.756 (P=0.000), respectively (Fig. 1).
3. Evaluation of the cut-off value
ROC curves were obtained by plotting a graph, in which the 
longitudinal axis showed sensitivity and the horizontal axis showed 
the false-positive rate. The nearest point to the left upper corner 
shows the most suitable cut-off point. To evaluate malignant po-
Table 2. Clinico-pathologic characteristics of patients




 Male 10  (38.5)
 Female 16  (61.5)
Location of tumor
 Proximal 12  (46.2)
  Middle   9 (34.6)
  Distal   4 (19.2)
 Whole 1  (3.8)
Size*
  <2 cm   3 (11.5)
  2~5 cm 15 (57.7)
  5~10 cm   6 (23.1)
  >10 cm 2 (7.7)
Mitotic count (/50 HPF)
 <5  25  (96.2)
 5~10 1  (3.8)
 >10 0  (0.0)
Risk group
  Very low risk 2 (7.7)
  Low risk 17 (65.4)
  Intermediate risk   5 (19.2)
  High risk 2 (7.7)
Immunohistochemical staining positivity
  C-KIT (CD 117) 22 (84.6)
  CD 34 24 (92.3)
  C-KIT (CD 117) & CD 34 20 (76.9)
Operative methods
  Laparoscopic surgery 11 (42.3)
  Open surgery 15 (57.7)
HPF = high-power fi  elds; SD = standard deviation. *Size is the single 
largest dimension. Park JW, et al.
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tential, we classified the NIH risk classification as “low-risk malig-
nancy” (very low-risk and low-risk) and “high-risk malignancy” 
groups (intermediate-risk and high-risk), and calculated the cut-
off point. The cut-off value of the MSU was 3.94 between the 
“low-risk malignancy” and “high-risk malignancy” groups and 
the area under the ROC curve was 0.872. The sensitivity and speci-
Fig. 1. Correlation between the maximum SUV uptake and Ki-67 index, tumor size, and mitotic count, and NIH risk group and tumor size. VL = 
very low risk; L = low risk; I = intermediate risk; H = high risk. *Pearson’s rank correlation; 
†Spearman’s rank correlation.
Table 3. Correlation between clinico-pathologic characteristics and maximum SUV uptake






MSU Correlation effi   ciency 1  0.888  0.854  0.791  0.756
 P-value  <0.001 <0.001 <0.001 <0.001
Tumor size Correlation effi   ciency    1  0.913  0.812  0.844
 P-value  <0.001 <0.001 <0.001
Ki-67 Correlation effi   ciency     1  0.732  0.786
 P-value <0.001 <0.001
Mitotic count Correlation effi   ciency       1  0.561
 P-value   0.003
NIH risk group Correlation effi   ciency      1
 P-value
*Pearson’s correlation analysis; 
†Spearman’s correlation analysis.Role of PET-CT in GIST
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ficity of the MSU for predicting the risk of malignancy were 85.7% 
and 94.7%, respectively (Fig. 2).
Discussion
Recently, many researchers have examined the post-operative 
indicators of malignant potential for GISTs, including the anatomic 
site, size, histomorphology, immunohistochemistry, and molecular 
genetics.(13) Size and an index of proliferation, either the Ki-67 
index or mitotic activity, appear to be the most robust and use-
ful prognostic factor post-operatively, even though recognizing 
absolute cut-offs are difficult to define. The outcome of the 2001 
NIH workshop was the proposal of a classification of GISTs in 
terms of the relative risk of aggressive behavior, rather than simply 
benign or malignant.(10) Many parameters have been proposed, 
but the morphologic features that have gained greatest acceptance 
as predictive of outcome are mitotic rate and tumor size,(14-18) 
Although these indices correlate with a relative risk of malignant 
behavior, the fact remains that lesions that are very small (＜2 cm) 
and lesions with very low mitotic rates (＜5/50 HPF) occasionally 
metastasize. Furthermore, this phenomenon of unpredictability is 
not rare in patients with GISTs, and has led to the use of terms, 
such as uncertain malignant potential.(10) Therefore, every GIST 
is now considered to have uncertain malignant potential, and the 
malignant potential of a GIST is difficult to diagnose before sur-
gery because the malignant potential is based on tumor diameter 
and mitotic index. It is relatively easy to calculate tumor diameter 
by anatomic imaging techniques, such as CT, EUS, and MRI, but 
not the mitotic index. This is a most important point regarding the 
need for pre-operative predictive factors of malignant potential. 
PET with FDG is an imaging technology that has demonstrated 
clinical utility in the evaluation of gastrointestinal malignancies. A 
growing body of evidence supports the use of FDG PET as an ac-
curate method to stage gastrointestinal malignancies. Tumors that 
demonstrate increased cellular metabolism are associated with in-
creased glycolysis and increased glucose transporter proteins. After 
intravenous administration, FDG accumulates in tumors throughout 
the uptake phase, providing an integrated signal of high glycolytic 
tissue activity throughout the entire body. Thus, FDG PET could 
be a rapid, non-invasive method to demonstrate the glycolytic ac-
tivity of a tumor and might be useful for assessing the malignant 
potential of a GIST. A markedly increased FDG uptake in GISTs 
has been documented in several studies and these studies indicated 
that FDG PET is useful for evaluating the effectiveness of imatinib 
mesylate, but not the malignant potential of the tumor.(19,20) In 
the current study we noted a significant correlation between FDG 
uptake and the mitotic rate, tumor diameter, and Ki-67 prolifera-
tion index (Fig. 1). The bioactivity of GIST had a correlation with 
FDG uptake because the mitosis reflected tumor cell proliferation, 
and the FDG uptake could evaluate the malignant potential of gas-
tric GISTs if an FDG PET scan is obtained before surgery. 
The cellular proliferative factors of GISTs include titrated thy-
midine, bromodeoxyuridine, Ki-67, and PCNA.(21) Ki-67 protein 
is present during all active phases of the cell cycle (G1, S, G2, and 
mitosis), but is absent from resting cells (G0). This antigen provides 
information regarding the proportion of active cells in the cell cycle 
and is an excellent marker for determining the so-called growth 
fraction of a given cell population.(22) The prognostic value of Ki-
67 has been observed in cancers of the breast, prostate, cervix, and 
soft tissue.(23) Elevated Ki-67 expression has been shown to be 
associated with increased tumor aggressiveness and invasiveness.
(24-26) In the current study, we noted a significant correlation 
between the Ki-67 index and SUV uptake (r=0.854, P＜0.001), 
thus a high SUV uptake can be high cell proliferation, and higher 
aggressiveness and invasiveness; We therefore hypothesized that 
elevated SUV values occur in highly proliferative GISTs, and the 
results of the current study supported our hypothesis.
GISTs could be classified as low- (very low- or low-risk) and 
high-risk for malignancy (intermediate- or high-risk) groups.
(10) We investigated the association between the MSU and risk 
categories based on morphologic features, including mitotic rate 
and tumor size by using ROC curves. The cut-off value of the 
MSU was 3.94 between very low- and low-, and intermediate- 
Fig. 2. Receiver operator characteristic (ROC) curves generated with 
maximum SUV uptake. Th  e  cut-off   value of the MSU was 3.94 between 
the “low-risk malignancy” and “high-risk malignancy” groups and the 
area under the ROC curve was 0.872. Park JW, et al.
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and high-risk groups based on the NIH risk classification (Fig. 
2). With a similar aim, Yamada et al.(27) reported that the cut-off 
values of FDG SUV were 2.2, 4.2, and 6.5 for low-, intermediate-, 
and high-risk groups, respectively, which was very similar to our 
results (3.94 vs. 4.2). We believe that tumors with a MSU >3.94 have 
a high-grade of malignancy. Therefore, although additional studies 
are needed, FDG PET could to determine the management strat-
egy for GISTs.
Many researchers have reported the malignancy or clinical be-
havior of GISTs.(5,18,28-30) At the European consensus meeting 
on the management of GISTs, it was suggested that all GISTs may 
need to be resected, but the controversy persists as to which is the 
best management strategy for relatively small lesions or those found 
incidentally during routine examinations because it is difficult to 
harvest a sufficient amount of tissue by endoscopic biopsy and pre-
dict malignant potentials of small GISTs, despite advances in mo-
lecular and immunohistochemical medicine. Recently, EUS-FNA 
was recommended as a safer technique that is essential for the 
pre-operative histologic diagnosis of gastrointestinal mesenchymal 
tumors.(27) At the European consensus meeting on the manage-
ment of gastrointestinal mesenchymal tumors, no consensus was 
achieved among experts regarding the need for a pre-operative 
diagnosis by biopsies, obtained by endoscopic ultrasound or per-
cutaneously because these tumors are very fragile, have the risk of 
tumor spillage, and may bleed easily.
FDG PET is a non-invasive modality. If a GIST shows hetero-
geneity, the metabolically active tissue can be distinguished from 
necrotic tissue by imaging the entire tumor in three dimensions. 
The maximum SUV of the tumor, rather than the average SUV, 
must be adopted for the analysis because the most metabolically-
active regions of the tumor drive the overall behavior of the tumor 
and averaging active areas with areas of cystic change or necrosis 
(areas with a very low SUV) would result in falsely low overall val-
ues.(24) In the current study, therefore, one nuclear radiologist cal-
culated the maximum SUV of the tumors in order to reduce bias.
In conclusion, The FDG PET scan is useful for assessing the 
bioactivity of gastric GISTs and less invasive than other techniques. 
Furthermore, it is easier to evaluate the malignant potential of gas-
tric GISTs, and the sensitivity and specificity predicting risk of ma-
lignancy were 85.7% and 94.7%, respectively, if a FDG-PET scan 
is used before surgery. It is reasonable to expect a gastric GIST with 
a high FDG uptake to have malignant potential.
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